Daewoong Pharma KRX:069620KOSPI

대웅제약 · Korean news coverage and regulatory filings, organized.

Articles, 24h42
Articles, 7 days147
DART filings, 7 days0
Articles tracked632since Sep 11

In Q2 2026, Daewoong Pharma reported revenue of ₩448bn, up 10.6% year on year, and operating profit of ₩68.1bn. Daewoong Pharma (대웅제약) appeared in 147 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 29 with 46 articles. The most common catalyst was risk & warnings (12). It was most often mentioned alongside Medy-Tox, Yuhan and Dongwha Pharm.

Filing signals Revenue & profit growth Screener

Daewoong Pharma quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩448bn+10.6%₩68.1bn
margin 15.2%
₩19.9bn
Q1 2026₩378bn+6.0%₩22.2bn
margin 5.9%
₩25.5bn
Q4 2025 derived₩397bn+7.9%₩43.3bn
margin 10.9%
₩85.7bn
Q3 2025₩412bn+14.9%₩56.9bn
margin 13.8%
₩47.3bn
Q2 2025₩405bn+12.5%₩57.9bn
margin 14.3%
₩40.1bn
Q1 2025₩356bn+6.2%₩38.7bn
margin 10.9%
₩19.8bn
Q4 2024 derived₩368bn+1.7%₩38.7bn
margin 10.5%
−₩11.5bn
Q3 2024₩358bn+5.2%₩37.3bn
margin 10.4%
₩28.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Daewoong Pharma top stories 2 weeks, by number of outlets

  1. 1
    대웅제약, 동탄시티병원과 MARS 2026서 ‘AI 스마트 병원’ 공개
    13 outlets · 13 articlesFirst report Oct 29 08:50 더바이오
  2. 2
    대웅제약, DNC 에스테틱스와 복합시술 전략 공유
    12 outlets · 12 articlesFirst report Oct 27 08:47 파이낸셜뉴스
  3. 3
    대웅제약 펙수클루, 헬리코박터 7일 제균요법 가능성 확인
    12 outlets · 12 articlesFirst report Oct 23 08:34 메디파나뉴스
  4. 4
    대웅제약, 아르헨티나서 나보타 마스터 클래스 개최
    11 outlets · 11 articlesFirst report Oct 20 08:43 메디포뉴스
  5. 5
  6. 6
    경찰, 대웅제약 지주사 압수수색…‘리베이트 의혹’ 수사확대
    9 outlets · 9 articlesFirst report Oct 29 18:31 매일경제Negative news

Latest Daewoong Pharma news Korean headlines